The FDA under the Trump administration is bringing a PTSD treatment back to the United States that veterans could previously get only abroad. The move puts a new tool in the hands of service members struggling with trauma, and the administration is framing it as a matter of cutting-edge care.
Veterans and others with PTSD, traumatic brain injury, and severe substance use disorders have long faced slow-moving traditional medicine. The treatment now returning to American shores was available overseas but not here. That gap has meant service members had to travel abroad to receive it.
The treatment’s journey home
The FDA’s decision comes after advocacy from veterans’ groups and military leaders who argued that U.S. service members should not have to leave the country to access effective care. The administration has claimed the move will give warfighters “cutting-edge, lifesaving care.”
Why the treatment was abroad
The treatment was previously available only abroad. That meant service members who needed it had to arrange travel and then undergo treatment far from home. The logistical burden was significant for families already strained by deployment.
The administration’s stated goal is to bring the treatment to the United States, where it can be delivered alongside existing mental health services. The move removes the need for veterans to cross borders to get help.
Who benefits from this change
The administration has framed the move as a win for service members and their families. The treatment addresses PTSD, traumatic brain injury, and severe substance use disorders, conditions that affect a significant portion of the veteran population.
The administration’s claim that the move will give warfighters “cutting-edge, lifesaving care” is the stated purpose of the action. Whether that claim holds up depends on how quickly the treatment becomes available in practice.
What the move means for veterans
The practical effect is that veterans can now receive the treatment in the United States without leaving the country. That changes the calculus for service members who might otherwise have skipped treatment because of the hassle of traveling abroad.
The move also signals a broader shift in how the federal government approaches veteran health care. Rather than sending service members abroad, the administration is bringing the treatment home.
Order of events
- Veterans and others with PTSD, TBI, and severe substance use disorders face slow-moving traditional medicine.
- A PTSD treatment was available only abroad.
- Advocacy from veterans’ groups and military leaders pushed for access in the United States.
- The FDA approved the treatment’s return to American shores.
- The administration claims the move delivers “cutting-edge, lifesaving care.”
The move removes a barrier that previously forced service members to travel abroad for care. That is a real improvement for veterans and their families.
The administration’s stated goal of providing warfighters with “cutting-edge, lifesaving care” is the stated purpose of the action. Whether that claim holds up depends on how quickly the treatment becomes available in practice.
Where the paper stands
The paper backs veterans and service members getting this treatment back in the U.S., and is against the FDA writing its own authority over what can come home. The administration’s stated goal is to bring the treatment to the United States, where it can be delivered alongside existing mental health services — a reasonable aim. But the FDA approving the treatment’s return on its own is a step the paper opposes, because it is an agency writing its own authority over private life.
The move removes the need for veterans to cross borders to get help, which is a real improvement for service members and their families. The paper wants to see the treatment become available quickly in practice, rather than just approved on paper.
Readers should watch for how the treatment actually rolls out across the country. The administration’s claim that the move will give warfighters “cutting-edge, lifesaving care” is the stated purpose of the action — but whether that claim holds up depends on how quickly the treatment becomes available in practice.
See the a run of 14 images at the Washington Examiner.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.